ERBB2 and breast cancer: According to the CLEOPATRA study, HER2-positive breast cancer patients received a regimen of combining pertuzumab with trastuzumab and docetaxel, and demonstrated a significantly improvement in overall survival compared with individuals who received a regimen of trastuzumab in combination with placebo and docetaxel [12, 21].